Processa Pharmaceuticals, Inc. Proceeds from Issuance or Sale of Equity
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from Issuance or Sale of Equity of $13.62 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2025-11-06
- Processa Pharmaceuticals, Inc. proceeds from issuance or sale of equity for the quarter ending 2025-09-30 was $2.86M, a 207.09% increase year-over-year.
- Processa Pharmaceuticals, Inc. proceeds from issuance or sale of equity for the quarter ending 2024-09-30 was $931.29K.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month |
|---|---|---|---|
| 2025-09-30 | $2.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $13.62M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $10.76M 10-Q · filed 2025-08-07 | ||
| 2024-09-30 | $931.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.21M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $6.28M 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |